Much has been made in recent days about the Cochrane Review, and subsequent media coverage, concerning anti-influenza drugs. Dr. Jeremy Rossman, Lecturer in Virology in the School of Biosciences, says that while the review questions the economic benefits of stockpiling Tamiflu, the drug could save many lives in the event of another serious influenza pandemic. Despite the apparently modest alleviation of influenza symptoms in adults, Dr. Rossman contends that this may still be of substantial benefit to public health in the case of a pandemic with highly-pathogenic influenza strains.
For more information, see Dr. Rossman’s full commentary.